AGTC: The New Leader in Ocular Gene Therapy with Sue Washer

<p>In this episode, <strong>Sue Washer, BS, MBA,</strong> discusses gene therapy in ophthalmology, ATGC’s clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology.</p> <ul> <li>Welcome to another exciting episode of Eye Care insider <strong><em>:13</em></strong></li> <li>About Washer <strong><em>1:51</em></strong></li> <li>Can you discuss what is gene therapy? How does it work on a basic level? <strong><em>4:53</em></strong></li> <li>How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? <strong><em>7:11</em></strong></li> <li>Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? <strong><em>11:08</em></strong></li> <li>Is there an estimated timeline that you have for initial data read out? <strong><em>14:56</em></strong></li> <li>You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? <strong><em>16:23</em></strong></li> <li>What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? <strong><em>20:56</em></strong></li> <li>Thank you so much for your insight into this fascinating topic <strong><em>23:22</em></strong></li> <li>How to find out more about AGTC <strong><em>23:31</em></strong></li> <li>Thank you for listening <strong><em>24:15</em></strong></li> </ul> <p><strong>Sue Washer, BS, MBA</strong> is the president and chief executive officer of AGTC.</p> <p>We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can contact AGTC through the company’s website at <a href= "https://agtc.com/">www.atgc.com</a>.</p> <p><strong>Disclosures:</strong> Mali reports he is founder and